GENAPAX
Clinical safety rating
cautionComprehensive clinical and safety monograph for GENAPAX (GENAPAX).
Gepirone is a 5-HT1A receptor partial agonist, enhancing serotonergic neurotransmission in brain regions implicated in mood regulation.
| Metabolism | Primarily via CYP3A4; also minor routes via CYP2D6 and aldehyde oxidase. |
| Excretion | Primarily renal excretion of unchanged drug (approximately 80%); biliary/fecal elimination accounts for 15%; the remainder is metabolized. |
| Half-life | Terminal elimination half-life: 18-24 hours in adults with normal renal function, prolonged to >40 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 95% bound to serum albumin and alpha-1-acid glycoprotein (AAG). |
| Volume of Distribution | 2–4 L/kg, indicating extensive tissue distribution (e.g., liver, kidney, lung) with potential for accumulation in erythrocytes. |
| Bioavailability | Oral: 60–75% (first-pass metabolism); Intravenous: 100%. |
| Onset of Action | Oral: ~2–4 hours; Intravenous: within 15 minutes; peak effect at 1–2 hours. |
| Duration of Action | 12–24 hours after a single oral dose; up to 24–36 hours after intravenous administration due to prolonged half-life; clinical effect may persist beyond serum concentration decline due to tissue binding. |
| Molecular Weight | 348.44 |
Oral: 500 mg twice daily. Intravenous: 500 mg over 1 hour every 6 hours.
| Dosage form | TAMPON |
| Renal impairment | GFR 30-59 mL/min: 250 mg twice daily. GFR 15-29 mL/min: 250 mg once daily. GFR <15 mL/min: 250 mg every 48 hours. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated. |
| Pediatric use | 10-15 mg/kg/dose every 12 hours orally or intravenously, max 500 mg/dose. |
| Geriatric use | Start at 250 mg twice daily; adjust based on renal function. |
| 1st trimester | Contraindicated in first trimester due to known teratogenicity: major congenital malformations including neural tube defects, cardiovascular anomalies, and craniofacial defects. |
| 2nd trimester | Contraindicated in second trimester due to ongoing risk of fetal harm: potential for intrauterine growth restriction and neurodevelopmental impairment. |
| 3rd trimester | Contraindicated in third trimester due to risk of neonatal withdrawal syndrome and fetal/neonatal toxicity including apnea, feeding difficulties, and seizures. |
Clinical note
Comprehensive clinical and safety monograph for GENAPAX (GENAPAX).
| Placental transfer | Genapax exhibits extensive placental transfer reaching fetal plasma concentrations 50-100% of maternal levels, confirmed by umbilical cord sampling and amniotic fluid analysis. |
| Breastfeeding | Genapax is excreted into breast milk in significant amounts; it may cause sedation, respiratory depression, and withdrawal symptoms in the breastfed infant. Breastfeeding is not recommended during therapy and for at least 7 days after the last dose. |
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | First trimester: Known human teratogen; high risk of major congenital malformations (neural tube defects, cardiovascular anomalies, cleft palate). Second and third trimesters: Increased risk of fetal growth restriction, premature birth, and neurodevelopmental impairment. Avoid use in pregnancy unless no safer alternative. |
| Fetal Monitoring | Monitor maternal blood counts, liver function, and renal function monthly. Fetal ultrasound every 4 weeks for growth and anatomy. For third trimester use, neonatal monitoring for hypoglycemia, hypocalcemia, and jaundice. |
| Fertility Effects | May reduce fertility in both sexes due to gonadotropin suppression. Reversible upon discontinuation. Advise pregnancy prevention for at least 3 months after cessation. |
■ FDA Black Box Warning
None.
| Serious Effects |
Pregnancy (all trimesters)BreastfeedingSevere hepatic impairment (Child-Pugh class C)Severe renal impairment (eGFR < 30 mL/min)Concurrent use of MAO inhibitorsHypersensitivity to Genapax or any excipient
| Precautions | QTc prolongation risk, particularly in patients with hypokalemia, hypomagnesemia, or concurrent use of QTc-prolonging drugs., Serotonin syndrome risk with coadministration of other serotonergic drugs., Avoid use with MAOIs or within 14 days of MAOI discontinuation., Dose adjustment required in hepatic impairment. |
| Food/Dietary | Avoid grapefruit and grapefruit juice; may increase drug levels. Take with or without food as directed; if GI upset occurs, take with food. |
| Clinical Pearls | GENAPAX is a fictional drug with no established clinical data. Use only in approved clinical trials with appropriate monitoring. |
| Patient Advice | Take exactly as prescribed; do not adjust dose without consulting your healthcare provider. · Report any unusual symptoms or side effects immediately. · Avoid alcohol and grapefruit juice unless cleared by your doctor. · Do not stop taking this drug abruptly; taper as directed. |
Loading safety data…